Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammatory and Oncology Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for VCAM-1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | VCAM-1 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View VCAM-1 Products |
| Gene Delivery | VCAM-1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View VCAM-1 Products |
| Benchmark Ab | Anti-VCAM-1 Recombinant positive control. |
View VCAM-1 Products |
| Validator | VCAM-1 siRNA Set For knockdown verification. |
View VCAM-1 Products |
| Related Target A | ITGA4 (VLA-4) Primary heterodimeric integrin receptor mediating leukocyte adhesion. |
View ITGA4 Products |
| Related Target B | ICAM-1 (CD54) Synergistic cell adhesion molecule co-expressed during endothelial activation. |
View ICAM-1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Glycosylation-dependent ligand binding (VLA-4 interaction) | HEK293 expressed (Native Glycosylation) preserving conformational epitopes |
| Endothelial cell adhesion modeling under flow/static conditions | Lentivirus for stable overexpression in endothelial cell lines |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live VCAM-1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for VCAM-1 therapeutics is intensifying, with major players shifting focus from traditional mAbs to targeted drug conjugates, CAR-T/NK cell therapies, and bispecific architectures. As first-generation anti-inflammatory therapies reach mature clinical phases, the next wave of R&D is targeting the tumor microenvironment, where VCAM-1 facilitates tumor cell survival, metastasis, and immune evasion.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Biogen, Academic Institutions | Multiple Sclerosis, Inflammatory Diseases | Blocking Assay (Need high-purity ECD-Fc) |
| CAR-T / CAR-NK | Biotech Startups, Clinical Centers | Solid Tumors, Metastatic Cancers | Target Cell Validation (Need Lentivirus for Stable Cell Line) |
| Small Molecule Inhibitors | Pharmaceutical Developers | Atherosclerosis, Autoimmune Disorders | Binding Selectivity (Need Mutant vs WT Proteins) |